Carvedilol for prevention of restenosis after directional coronary atherectomy : Final results of the european carvedilol atherectomy restenosis (EUROCARE) trial

In addition to its known properties as a competitive, nonselective beta and alpha-1 receptor blocker, carvedilol directly inhibits vascular myocyte migration and proliferation and exerts antioxidant effects that are considerably greater than those of vitamin E or probucol. This provides the basis fo...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Circulation (New York, N.Y.) N.Y.), 2000-04, Vol.101 (13), p.1512-1518
Hauptverfasser: SERRUYS, P. W, FOLEY, D. P, BONNIER, H, WIJNS, W, BETRIU, A, HAUF-ZACHARIOU, U, VAN SWIJNDREGT, E. M, MELKERT, R, SIMON, R, HÖFLING, B, PUEL, J, GLOGAR, H. D, SEABRA-GOMES, R, GOICOLEA, J, COSTE, P, RUTSCH, W, KATUS, H
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:In addition to its known properties as a competitive, nonselective beta and alpha-1 receptor blocker, carvedilol directly inhibits vascular myocyte migration and proliferation and exerts antioxidant effects that are considerably greater than those of vitamin E or probucol. This provides the basis for an evaluation of carvedilol for the prevention of coronary restenosis. In a prospective, double-blind, randomized, placebo-controlled trial, 25 mg of carvedilol was given twice daily, starting 24 hours before scheduled directional coronary atherectomy and continuing for 5 months after a successful procedure. The primary end point was the minimal luminal diameter as determined during follow-up angiography 26+/-2 weeks after the procedure. Of 406 randomized patients, 377 underwent attempted atherectomy, and in 324 (88.9%), a
ISSN:0009-7322
1524-4539
DOI:10.1161/01.CIR.101.13.1512